1. Baum JK, Bookstein JJ, Holtz F, Klein EW: Possible association between hepatomas and oral contraceptives.Lancet9: 926–929, 1973.
2.
2. Sturtevant FM: Oral contraceptives and liver tumors in Controversies in Contraception.Moghissi KS (editor). Williams and Wilkins, Baltimore, 1979, Chapter 7.
3.
3. Klatskin G: Hepatic tumors: Possible relationship to use of oral contraceptives.Gastroenterology73: 386–394, 1977.
4.
4. Caroli J, Paraf A, Charbonnier A, Vallin J: Implantations d'oestrogenese apparement suivies d'un cancer primitif du foie.Rev Intern Hepatol3: 497, 1953.
5.
5. Christopherson WM, Mays ET, Barrows GH: Liver tumors in women on contraceptive steroids.J Obstet Gynecol46: 221–223, 1975.
6.
6. Neuberger J, Nunnerley HB, Davis M, Portman B, Laws JR, Williams R: Oral contraceptive-associated liver tumours: Occurrence of malignancy and difficulties in diagnosis.Lancet1: 263, 1980.
7.
7. Christopherson WM, Mays ET, Barrows GH: Liver tumors in young women: A clinical pathologic study of 201 cases in the Louisville registry in Progress in Surgical Pathology vol 2. Fenoglio CM, Wolff M (editors). Masson Publishing USA, New York, 1980, pp. 187–205.
8.
8. Nissen ED, Kent DR, Nissen SE: Role of oral contraceptive agents in the pathogenesis of liver tumors in Liver Carcinogenesis.Lapis K, and Johannessen JV (editors). Hemisphere Publishing, New York, 1979, p. 61.
10. Barrows GH, Christopherson WM, Drill VA: Liver lesions and oral contraceptives.J Toxicol Environ Health3: 219–230, 1977.
11.
11. Reznik-Schuller H: Carcinogenic effects of diethylstilbestrol in male Syrian golden hamsters and European hamsters.J Natl Cancer Inst62: 1083–1088, 1979.
12.
12. Schardein JL, Kaump DH, Woosley ET, Jellema MM: Long term toxicologic and tumorigenesis studies on an oral contraceptive agent in albino rats.Toxicol Appl Pharmacol16: 10, 1970.
13.
13. Lang R, Redmann U: Nonmutagenicity of some sex hormones in the Ames Salmonella/microsome mutagenicity test.Mutat Res67: 361–365, 1979.
14.
14. Reuber MD: Influence of hormones on N-2-fluorenyldicatamide-induced hyperplastic hepatic nodules in rats.J Natl Cancer Inst43: 445–451, 1969.
15.
15. Taper HS: The effect of estradiol-17-phenylpropionate and estradiol benzoate on n-nitrosomorpholine-induced liver carcinogenesis in ovariectomized female rats.Cancer42: 462–467, 1978.
16.
16. Yager JD, Yager R: Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats.Cancer Res40: 3680–3685, 1980.
17.
17. Wanless IR, Medline A: Role of estrogens as promoters of hepatic neoplasia.Lab Invest46: 313–320, 1982.
18.
18. Christopherson WM, Mays ET: Liver tumors and contraceptive steroids. Experience with the first one hundred registry patients.J Natl Cancer Inst58: 167–172, 1977.
19.
19. Barrows GH, Christopherson WM: Human liver tumors in relation to steroid usage.Perspectives in Environmental Health (In press, 1982).
21. Barrows GH, Christopherson WM, Mays ET, Reese D: Estrogen and progesterone receptor status of benign liver tumors.Am J Clin Pathol75: 872–873, 1981.
22.
22. Sturtevant FM: Liver tumors and oral contraceptives.Pan-American Conference on Fertility and Sterility, Dorado Beach, Puerto Rico, February 4–12, 1977.
23.
23. Lee S, Chen C: Liver microsomes dimethylate mestranol and some of its effects on drug metabolism.Steroids18: 565–575, 1971.
24.
24. Rooks JB, Howard HW, Ishak KG, Strauss LT, Greenspan JR, Paganini A, Tyler CW: Epidemiology of hepatocellular adenoma.J A M A242: 644–648, 1979.
25.
25. Grabowski M, Stenram U, Vergvist A: Focal nodular hyperplasia of the liver, benign hepatomas, oral contraceptives and other drugs affecting the liver.Acta Pathol Microbiol Scand Sect A88: 615–622, 1975.
26.
26. Edmondson HA, Reynolds TB, Henderson B, Benton B: Regression of liver cell adenomas associated with oral contraceptives.Ann Intern Med86: 180–182, 1977.
27.
27. Ross D, Pina J, Mirza M, Galvan A, Ponce L: Regression of focal nodular hyperplasia after discontinuation of oral contraceptives.Ann Intern Med85: 203–204, 1976.
30. Almen T, Hartel M, Nylander G, Olivecronah J: The effect of estrogen on the vascular endothelium and its possible relation to thrombosis.Surg Gynecol Obstet140:938–940, 1975.
31.
31. Howell RR, Stevenson RE, Ben-Menachem Y, Phyliky RL, Berry DH: Hepatic adenomata with type I glycogen storage disease.J A M A236: 1481–1484, 1976.
32.
32. Weil R, Koep LJ, Starzl TE: Liver resection for hepatic adenoma.Arch Surg114: 178–180, 1979.
34. Johnson FL, Feagler JR, Lerner KG, Majerus PW, Siegel M, Hartmann JR, Thomas ED: Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma.LancetII: 1273–1276, 1972.
35.
35. Davis M, Portman B, Searle M, Wright R, Williams R: Histologic evidence of carcinoma in a hepatic tumour associated with oral contraceptives.Br Med J4: 496–498, 1975.
36.
36. Galloway SJ, Casarella WS, Lattes R, Seaman W: Minimal deviation hepatoma: A new entity.Am J Roentgenol125: 184–192, 1975.
37.
37. Okuda K, Peters RI: Hepatocellular Carcinoma.John Wiley and Sons, New York, 1976, p. 152.
38.
38. Berman MM, Libbey NP, Foster JH: Hepatocellular carcinoma. Polygonal cell type with fibrous stroma-an atypical variant with a favorable prognosis.Cancer46: 1448–1455, 1980.
39.
39. Christopherson WM: Possible etiologic factors for some malignant hepatic tumors in Gastrointestinal Cancer.Stroehlein JR, Romsdahl MM (editors). Raven Press, New York, 1981, pp. 257–269.
40.
40. Ory WM, Rosenfield A, Landrum LC: The pill at 20: An assessment.Fam Plann Perspect12: 278–283, 1980.